Large-Scale Restructuring Following Sharp Decline in Vaccine Revenue

German biotech company BioNTech (BNTX) is undergoing significant workforce reductions due to declining sales of Comirnaty, its mRNA vaccine co-developed with Pfizer (PFE) against COVID-19, following the end of the pandemic. The company plans to close or sell its manufacturing facilities in Idar-Oberstein, Marburg, Tübingen, Germany, and Singapore by 2027, and will lay off approximately 1,860 employees, representing 22% of its workforce. All COVID-19 vaccine production will be transferred to Pfizer by the end of 2026, which is a crucial financial strategy to preserve liquidity in response to the end of the pandemic-driven demand.

Strategic Shift to Oncology Pipeline

With this large-scale workforce reduction, BioNTech aims to reduce costs by approximately €500 million annually by 2029, and will focus on investing in the development of its next-generation oncology pipeline. The company is concentrating its research efforts on mRNA-based cancer vaccines and cell therapies, including the BNT211 CAR-T therapy, which is currently in clinical trials. Furthermore, with the founders, Uğur Şahin and Özlem Türeci, stepping down from management roles at the end of 2026 to establish a new mRNA startup, BioNTech is transforming into a fully-fledged second-generation oncology company.

Layoffs in Biotech Ventures Due to Clinical Failures and Regulatory Hurdles

Small and medium-sized biotech companies are also facing significant restructuring pressures due to clinical failures and rejections by regulatory authorities. Vistagen Therapeutics (VTGN) reduced its workforce by 20% after its intranasal spray, fasedienol (PH94B), targeting the pheromone receptor, failed to achieve its primary endpoint in the Phase 3 PALISADE-3 trial in December 2025 for the treatment of social anxiety disorder (SAD). Additionally, Replimune Group (REPL), an oncology biotech company, had to lay off a significant portion of its workforce, totaling 224 employees, after its oncolytic immunotherapy candidate, RP1 (vusolimogene oderparepvec), targeting HSV-1, in combination with nivolumab, received a second complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in April 2026 for the treatment of melanoma.

Proactive Financial Defense and R&D Restructuring by Big Pharma

This wave of layoffs is not limited to small and medium-sized companies but is also spreading to large, financially stable global pharmaceutical companies. Takeda Pharmaceutical (TAK) has announced plans to reduce its workforce by more than 600 employees in the United States, including in Massachusetts, as part of a $1.3 billion company-wide restructuring program aimed at driving the launch of upcoming new drugs and R&D investments. Merck & Co. (MRK) is also proactively cutting costs by reducing its global workforce by 8% to prepare for the patent expiration of Keytruda, its blockbuster immune checkpoint inhibitor with annual sales of $25 billion, and to address the declining demand for Gardasil, its HPV vaccine.